Darling Ingredients Inc. announced that it has launched Nextida GC, a new collagen peptide that displayed a reduction in the post-meal glucose spike in healthy individuals. The clinical trial1, conducted by Darling Ingredients’ premier collagen and gelatin brand Rousselot, showed that a 5-gram or 10-gram dose orally 30 minutes before a meal significantly lowered post-meal glucose spike in the blood by an average of 42%2.
“Darling Ingredients has unlocked the next wave of collagen-based solutions that are truly revolutionary. Produced through our proprietary process, we have discovered a way to use natural collagen for targeted health benefits,” said Randall C. Stuewe, Chairman and CEO.
Nextida GC is the first of many collagen-based solutions with targeted health benefits that the company is developing.
Also Read: Real Chemistry and Corval Join Forces in Biopharma
“Our scientific work continues to demonstrate how collagen can effectively be used to target common health and wellness benefits,” Stuewe said. “Built on science with patents pending, we continue to unveil the power of collagen to help us live happy, healthier lives.”
Darling Ingredients Inc. takes material from the animal agriculture and food industries, and transforms them into valuable ingredients that nourish people, feed animals and crops, and fuel the world with renewable energy. The company operates over 260 facilities in more than 15 countries and processes about 15% of the world’s animal agricultural by-products, produces about 30% of the world’s collagen (both gelatin and hydrolyzed collagen), and is one of the largest producers of renewable energy.
SOURCE: PRNewswire